Full Text View
Tabular View
No Study Results Posted
Related Studies
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
This study is currently recruiting participants.
Verified June 2013 by Boehringer Ingelheim Pharmaceuticals
Study NCT01345669   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on April 28, 2011.   Last Updated on June 12, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Head and Neck Neoplasms
Additional conditions recognized in this trial
Carcinoma, Squamous Cell
Neoplasms
Neoplasms, Squamous Cell
More general conditions related to this trial
Carcinoma
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
Placebo
Afatinib
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services